{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-000957","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2024-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.453307+00:00","generated_at":"2026-05-31T16:47:49.675536+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Immunic appoints ex-Roche neuroscience head Skerjanec to board; 150K options granted","bullets":["Simona Skerjanec appointed to board effective July 22, 2024 as Class I director until 2027 annual meeting.","Received inducement grant for 100K shares ($1.46) vesting monthly over 3 years; additional 50K shares vesting over 1 year.","Board size increased from 7 to 8 members.","Skerjanec led Roche's Ocrevus commercial launch, generating over $1B in first 10 months.","Company approaching late-stage readouts for vidofludimus calcium in MS; recently hired ex-Novartis/Biogen COO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-000957","json":"https://secwatch.observer/filing/0001193805-24-000957.json","markdown":"https://secwatch.observer/filing/0001193805-24-000957.md","text":"https://secwatch.observer/filing/0001193805-24-000957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000957/0001193805-24-000957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000957/e663800_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T16:47:49.675536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"46d67b1abd","claim":"Simona Skerjanec was appointed as Director at IMMUNIC, INC..","evidence_excerpt":"On July 24, 2024, Immunic, Inc. (the “Company”) announced the appointment of Simona Skerjanec, M.Pharm, MBA, as a member of the board of directors (the “Board”) of the Company, effective as of July 22, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000957/0001193805-24-000957-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}